Slimirex - Natural Weightloss Supplement

Weight Loss Blog

Trademark License Agreement

 

Trademark License Agreement

Bioperine® supplied by Sabinsa Corporation is an all-natural patented product designed to enhance the absorption of nutritional compounds. Due to the unique properties of this ingredient and the language used in the patent, the Customer agrees to the following criteria, terms and conditions which Sabinsa and the Customer deem necessary to assure the protection of the intellectual property rights, identity and integrity of Bioperine® in the marketplace. With respect to any product or formulation containing Bioperine®, the Customer agrees:

  • To purchase Bioperine® directly from Sabinsa Corporation or through their accredited exclusive agent in their country.
  • To list the name Bioperine® on all product(s) ingredient panels and submit label to Sabinsa for final approval.
  • To identify Bioperine® as a trademark of Sabinsa Corporation and to include Bioperine® logo on the product label and in advertising materials. Customer will be given indemnification if the Bioperine® logo infringes with any other trademark or patents.
  • It will not display the name, identify or market Bioperine ® with any generic material, logo or artwork not supplied or approved by Sabinsa. Based on double blind clinical data, Sabinsa recommends Bioperine® in the amount of 5 mg per dose but does not require this level in customer’s formulation.

This agreement applies to all products containing Bioperine® whether manufactured, sold, distributed or marketed by the customer and/or others. Other than for use in manufacturing the customer’s own product, the customer shall not resell or supply Bioperine ® in the bulk raw material form, either directly or indirectly, to any third party. Sabinsa will supply only to the manufacturer and i f the customer is not the manufacturer, the customer shall inform Sabinsa of the name and address of the customer’s manufacturer. If the customer is a contract manufacturer, and supplies, but does not own or control, the finished product, the contract manufacturer shall inform its customer to the terms and conditions of this agreement. A license agreement must be executed by each of the contract manufacturers, Customers and Sabinsa Corporation. As an addendum to this agreement, the Customer shall provide Sabinsa with a current list of products containing Bioperine®. Addendum is to be updated annually by the customer listing additions/deletions. Use of Bioperine® requires that the provisions of this agreement be understood and accepted by all who use and market it. Sabinsa Corporation may refuse to supply or sell Bioperine® to any person or entity who fails to honor this agreement; however, customer will be given reasonable time to sell through inventory after receipt of written notification detailing the reasons for terminating this agreement. Sabinsa Corporation may also pursue any and all legal rights, remedies and recourse in the event of a breach of this Agreement. This Agreement is binding upon the customer, its successors and assignee . This Agreement shall be governed by, enforced under and interpreted in accordance with the laws of the State of New Jersey, to which jurisdiction the parties, hereby, submit.

Acceptance of Agreement by authorized company representative:

Company / Customer : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Name (please print) : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Title : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Signature : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Date : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

For Sabinsa use only

Trademark License Approval by : . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . .

Date : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(revised July, 2000) US Patents #5,536,506, #5,744,161 and #5,972,382, and #6,054,585. International Patents pending

Bioperine®

Trademark License Agreement Product Addendum

The following product(s) are submitted by the Customer for approval to include the ingredient Bioperine®, according to the terms and conditions of the Trademark License Agreement. Bioperine® is recommended at 5 mg per dose. Please indicate the brand and product trade name.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Name of Marketing Company : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Name and address of Manufacturing Company (if different from Marketing Company): . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Date : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sabinsa Approval by : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Date : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . .

[ Read More ]

Booklet For Reference

 
Bioperine Logo

Nature’s own Thermonutrient® and Natural bioavailability enhancer

Bioperine Manual

Authors:
Muhammed Majeed, Ph.D., Vladimir Badmaev, M.D., Ph.D., Lakshmi Prakash, Ph.D.

82 pages, $7.95

NUTRISCIENCE PUBLISHERS, INC.

[ Read More ]

Peer Reviewed Article

 

Planta Med. (1998) 64(4):353-356

Influence Of Piperine On The Pharmacokinetics Of Curcumin In Animals And Human Volunteers

G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran and P.S. Srinivas

ABSTRACT
The medicinal properties of curcumin obtained from Curcuma longa L. cannot be utilized because of poor bioavailability due to its rapid metabolism in the liver and intestinal wall. In this study, the effect of combining piperine, a known inhibitor of hepatic and intestinal glucuronidation, was evaluated on the bioavailability of curcumin in rats and healthy human volunteers. When curcumin was given alone, in the dose 2 g/kg to rats, moderate serum concentrations were achieved over a period of 4 h. Concomitant administration of piperine 20 mg/kg increased the serum concentration of curcumin for a short period of 1-2 h post drug. Time to maximum was significantly increased (P < 0.02) while elimination half life and clearance significantly decreased (P < 0.02) and the bioavailability was increased by 154%. On the other hand in humans after a dose of 2 g curcumin alone, serum levels were either undetectable or very low. Concomitant administration of piperine 20 mg produced much higher concentrations from 0.25 to 1 h post drug (P < 0.01 at 0.25 and 0.5 h; P < 0.001 at 1 h); the increase in bioavailability was 2000%. The study shows that in the dosages used, piperine enhances the serum concentration, extent of absorption and bioavailability of curcumin in both rats and humans with no adverse effects.


Nutrition Research (1999) 19(3) 381-388

Piperine, An Alkaloid Derived From Black Pepper, Increases Serum Response Of Beta-Carotene During 14-Days Of Oral Beta-Carotene Supplementation

Vladimir Badmaev, M.D., Ph.D., Muhammed Majeed, Ph.D. and Edward P. Norkus Ph.D.

ABSTRACT
The effectiveness of an extract from the fruit of black pepper, consisting of a minimum of 98% pure alkaloid piperine was evaluated for its ability to improve serum response of beta-carotene during oral supplementation using a double-blind, crossover study design. Subjects were randomly selected to ingest a daily beta-carotene dose (15 mg) either with 5 mg of piperine or placebo during each of two 14-day supplementation periods. Inter-subject variability in pre-supplementation serum beta-carotene levels was minimized by limiting the selection of volunteers to healthy adult males with fasting serum beta-carotene values < 20 mcg/dL. The results indicate that significantly greater increases (p < 0.0001) in serum beta-carotene occurred during supplementation with beta carotene plus piperine (49.8±9.6 mcg/dL vs. 30.9±5.4 mcg/dL) compared to beta-carotene plus placebo. Supplementation with beta-carotene plus piperine for 14 days produced a 60% greater increase in area under the serum beta- carotene curve (AUC) than was observed during supplementation with beta-carotene plus placebo. We suggest that the serum response during oral beta-carotene supplementation is improved through non-specific, thermogenic property(s) of piperine described in this paper as thermonutrient action.


J. Nutr. Biochem. (2000) 11: 109-113

Piperine Derived From Black Pepper Increases The Plasma Levels Of Coenzyme Q10 Following Oral Supplementation

Vladimir Badmaev, M.D., Ph.D., Muhammed Majeed, Ph.D., and Lakshmi Prakash, Ph.D.

ABSTRACT
An extract from the fruits of black pepper consisting of a minimum of 98% pure piperine was evaluated in a clinical study using a double-blind design. The relative bioavailability of 90 mg and 120 mg of coenzyme Q10 administered in a single dose experiment or in separate experiments for 14 and 21 days with placebo or with 5 mg of piperine was determined by comparing measured changes in plasma concentration. The inter-subject variability was minimized by limiting the selection of individuals to healthy adult male volunteers with (pre-supplementation) fasting coenzyme Q10 values between 0.30 and 0.60 mg/L. The results of a single dose study and the 14-day study indicate smaller, but not significant, increases in plasma concentrations of coenzyme Q10 in the control group compared to the group receiving coenzyme Q10 with a supplement of piperine. Supplementation of 120 mg of coenzyme Q10 with piperine for 21 days produced a statistically significant (p=0.0348), approximately 30% greater, area under the plasma curve (AUC) than observed during supplementation with coenzyme Q10 plus placebo. It is postulated that the bioenhancing mechanism of piperine to increase plasma levels of supplemental coenzyme Q10 is nonspecific and possibly based on its description in the literature as a thermonutrient.

[ Read More ]

Press Release

 

Sabinsa Corporation Granted Fourth Patent on Bioperine®

May 10, 2000 PISCATAWAY, NJ – Sabinsa Corporation has been granted its fourth patent on* Bioperine®, a proprietary ingredient which has been clinically shown to increase the bio availability of nutritional supplements, thus making them more effective. US patent #6,054,585 was awarded April 25, 2000. The new patent awarded to Sabinsa is a process patent, explaining how the material is made and protecting Sabinsa’s patent rights. Previous patents insured Sabinsa exclusive rights to offer piperine, the active compound in Bioperine® extracted from black pepper, regardless of its source, for use in nutritional compounds. Practically speaking, this means that no one can legally market or sell piperine for nutritional compounds except Sabinsa or its designated licensees. The only clinical studies done with piperine for nutritional purposes are with Bioperine®.

Please contact Sabinsa Corporation for more information in New Jersey at 732-777-1111 or in Utah at 801-465-8400.

Sabinsa Corporation is an application-oriented manufacturing and marketing company which manufacturers and supplies Phytonutrients, Ayurvedic herbal extracts and specialty fine chemicals used for nutritional, pharmaceutical and food products. Sabinsa distinguishes itself by its extensive research support for its customers and products, as well as the scientific credentials of its key technical staff.

* Bioperine® is a registered trademark of the Sabinsa Corporation

Bioavatilability Enhancing Phytonutrient Receives European Trademark

May 10, 2000 PISCATAWAY, NJ – Sabinsa Corporation’s Bioperine® trademark has been officially accepted and recognized as a trademark in Europe. Sabinsa received a Certificate of Registration 000286922 for the Bioperine® trademark that provides protection in the 15 member states of the European Union (EU).

Sabinsa Corporation Nominated for Prestigious Edison Award

PISCATAWAY, NJ – Sabinsa Corporation was recently nominated for the 1999 Thomas Alva Edison Patent Award in the Health & Medical category. This award is granted annually for recognizing the worldwide impact of science and technology. Sabinsa was selected based upon its patents for Bioperine®, a proprietary ingredient which enhances nutrient bioavailability and absorption.

Other finalists included Rutgers University, Union Carbide Company, Lucent Technologies, and Bell labs. A total of eight finalists were selected. The award is bestowed by the New Jersey Research & Development Council.

Commenting on the events of the evening, Sabinsa’s President and CEO Dr. Muhammed Majeed noted, “Although we didn’t win the award for our category, we consider ourselves winners just for being one of the finalists. We were competing against multi-billion dollar organizations and rubbing shoulders with some of the brightest research minds in the country. There were no losers here tonight.”

Sabinsa Corporation, which has pioneered the introduction of several Ayurvedic herbal extracts in the US market, is an application-oriented manufacturing and marketing company which manufacturers Phytonutrients, Ayurvedic herbal extracts and fine chemicals used for nutritional, pharmaceutical, cosmeceutical and food products. Sabinsa distinguishes itself by its extensive research support for its customers and products, as well as the scientific credentials of its technical staff.

Sabinsa Corporation Granted Third Patent on Bioperine®
Bioavailability Enhancing Phytonutrient

PISCATAWAY, NJ — Sabinsa Corporation has been granted a third patent on Bioperine®, the proprietary ingredient which has been clinically shown to increase the bio availibility of nutritional supplements, thus making them more effective.

This US patent, # 5,972,382, was granted October 26, 1999. Previous patents are US patent #5,536,506, granted July 16, 1996, and US patent # 5,744,161, granted April 28, 1998.

Piperine is the active compound extracted from black pepper which is responsible for Bioperine’s bioavailability enhancing properties in nutritional compounds. The patents awarded to Sabinsa grant the company the exclusive right to offer piperine, regardless of its source, for use in nutritional compounds. Practically speaking, this means that no one can legally market or sell piperine for nutritional compounds except Sabinsa or its designated licensees.

The only clinical studies done with piperine for nutritional purposes are with Bioperine®. Bioperine® is the only piperine compound clinically tested for safety and efficacy. Recent studies include a March 1999 in the Nutrition Research Journal: Piperine Increases Serum Response Of Beta-Carotene During 14 Days of Oral Beta Carotene Supplementation. Another study confirmed for publication in early 2000 will appear in the Journal of Nutritional Biochemistry on CoQ10 and Bioperine®.

Bioperine® was designed to address the problem of limited nutrient bioavailability, which may be caused by a variety of conditions such as old age, limited diet choices or a compromised gastrointestinal tract. “The usual way these conditions are compensated for involved increased dosage. Bioperine® provides an alternative method for improving nutritional status by increasing the amount of nutrients absorbed by the body.” There are a number of companies offering finished products that include Bioperine®. Sabinsa requires that a licensing agreement be executed with each marketing company prior to selling Bioperine®, and that the ingredient logo appear on the label to help consumers identify products containing Bioperine®.

In other related news, Sabinsa was recently nominated by the New Jersey R&D Council as one of three finalists for the prestigious Thomas Alva Edison Patent Award in the Health & Medical category. This award is granted annually to recognize the worldwide impact of science and technology. Sabinsa was selected based upon its patents for the use of Bioperine®.

Sabinsa Corporation is an application-oriented manufacturing and marketing company which manufacturers and supplies Phytonutrients, Ayurvedic herbal extracts and specialty fine chemicals used for nutritional, pharmaceutical and food products. Sabinsa distinguishes itself by its extensive research support for its customers and products, as well as the scientific credentials of its key technical staff.

Sabinsa Corporation’s Dr. Majeed & Dr. Badmaev Publish Peer-Reviewed article in Nutrition research magzine

January 29, 1999 PISCATAWAY, NJ – Sabinsa Corporation’s founder Muhammed Majeed, PhD and Vice President of Scientific and Medical Affairs, Vladimir Badmaev, MD, PhD., have authored an article to appear in the peer-reviewed journal, Nutrition Research.

The article, “Piperine, an alkaloid derived from black pepper increases serum response of beta-carotene during 14 days of oral beta-carotene supplementation” to appear in Vol.19 No.3, (March 1999 pages 385-392) issue details the clinical study involving Bioperine® and Beta-Carotene. Bioperine® is a multi-patented ingredient from Sabinsa Corporation, standardized for a minimum 98% piperine from the fruits of the Piper nigrum plant (black pepper). Bioperine® has been shown to increase the bioavailability of other supplements in separate clinical studies also.

Sabinsa Corporation is an application-oriented manufacturing and marketing company which manufactures and supplies quality assured phytonutrients, standardized herbal extracts and specialty fine chemicals used for nutritional, pharmaceutical and food products. Sabinsa distinguishes itself by its extensive research support for its customers and products, as well as the scientific credentials of its key staff.

October 28, 1995 Sabinsa Corporation’s founder Receives President’s Award in New Delhi, India

NEW DELHI, INDIA – Dr. Muhammed Majeed, founder, President and CEO of Sabinsa Corporation received the President’s Award for Quality and Innovation from Dr. Shankar Dayal Sharma, President of India on October 11, 1995. Sabinsa’s research and manufacturing facility located in India was named company of the year.

“Dr. Majeed, your contributions … are appreciated as a mechanism for human resource development and as an agent of change,” said Dr. Sharma in presenting the award. “I hope that this award will inspire you to further achievements in the years ahead.”

The company was selected because of its innovative practices, specifically for implementing the manufacturing process of L-Selenomethionine, making it one of only two companies in the world to manufacture this unique and safe form of selenium. The company was also cited for its development of Citrin®, the first standardized Garcinia extract in the world, and Bioperine®, which has been shown in clinical testing to improve absorption of essential nutrients with which it is formulated.

Sabinsa Obtains emergency injunction against alchem International in Patent Infringement case at Supplyside East

Secaucus, NJ – For the first time, a foreign company engaging in alleged Intellectual Property (IP) theft at a dietary supplements industry trade show has been stopped in its tracks.

Sabinsa Corporation, known for vigorously protecting its IP, obtained an emergency injunction from the United States District Court against Alchem International, Ltd. when it was observed that the company was offering to sell products which infringed upon two of Sabinsa’s patented ingredients, Forslean® and Bioperine® , at SupplySide East in Secaucus NJ.

According to Mark C. Sysler, Sabinsa’s Sr. EVP for Marketing and Sales, defending a company’s Intellectual Property against some foreign patent infringers is a struggle. These companies will attend or exhibit at a trade show, offer to sell ingredients that are protected by a US patent, and leave the country before action can be taken by the patent holder. They then follow up on those leads from overseas and it is difficult to pursue legal action against them.

In this case, Sysler went before US district Judge Pisano on Tuesday May 6, 2003, just after the trade show opened. The judge issued a temporary order restraining Alchem from:

“1. Infringing Sabinsa ‘s United States patent no. 5,804,596 either directly, contributorily or by inducement, by importing, using, making, selling or offering to sell any coleus forskohlii extract in a concentration of 3% or greater, specifically including any sale, advertising, promotion, display or mention of the products at the Supply Side East trade show presently taking place at the Meadowlands Exposition center in Secaucus New Jersey and

2. from infringing Sabinsa ‘s United States patent no. 5,972,382 either directly, contributorily or by inducement, by importing, using, making, selling or offering to sell any piperine extract from black pepper in any concentration, specifically including any sale, advertising, promotion, display or mention of the products at the Supply Side East trade show presently taking place at the Meadowlands Exposition center in Secaucus New Jersey.”

Sabinsa Corporation, which has pioneered the introduction of several Ayurvedic herbal extracts in the US market, is an application-oriented manufacturing and marketing company which manufacturers Phytonutrients, Ayurvedic herbal extracts and specialty fine chemicals used for nutritional, pharmaceutical, cosmeceutical and food products. Sabinsa distinguishes itself by its extensive research support for its customers and products, and the scientific credentials of its key technical staff.

[ Read More ]

Curcumin

 

The objective of this study was to evaluate the bioavailability of curcumin co-administered with Bioperine® in animals and human volunteers. Curcumin is a phenolic phytochemical obtained from turmeric ( Curcuma longa L). It has been scientifically researched that Curcumin has effective therapeutic outcome acting as an antioxidant, anti-inflammatory, antispasmodic, anticoagulant, anticarcinogenic, immunomodulatory activities and even in wound healing. It has been found that the therapeutic effectiveness of curcumin is often limited due to its poor absorption from the GI tract. When taken orally only traces appear in the blood whereas most of the dose is excreted though the feces.

Piperine was found to enhance the bioavailability of Curcumin both in preclinical studies and in studies on human volunteers.

BIOAVAILABILITY STUDIES: CURCUMIN & BIOPERINE®

Pharmacokinetic parameters (mean ± SEM) of oral curcumin 2g/kg alone and in combination with Bioperine® 20 mg/kg in rats (n= 6).

Parameters
Curcumin alone
2 g/kg
Curcumin + Bioperine®
2g/kg + 20mg/kg
Cmax (mg/ml)
1.35 ± 0.23
1.80 ± 0.16
Tmax (h)
0.83 ± 0.05
1.29 ± 0.23″
t1/2(a) (h)
0.31 ± 0.07
0.47 ± 0.03
t1/2(el) (h)
1.70 ± 0.58
1.05 ± 0.18″
AUC(0 – tn) (mg/h/ml)
2.36 ± 0.28
3.64 ± 0.31
Vd (L/kg)
1366.00 ± 248.70
782.90 ± 193.90
Cl(L/h)
713.00 ± 12.00
495.90 ± 37.08″
  • “P < 0.02: Statistical significance by Student’s “t” test
  • Cmax: Maximum serum concentration
  • Tmax: Time to reach maximal serum concentration
  • t1/2(a): Absorption half-life
  • t1/2(el): Elimination half-life
  • AUC(0 – tn): Area under the concentration time curve
  • Vd: Volume of distribution
  • Cl: Total clearance

EFFECT OF BIOPERINE® ON SERUM CONCENTRATIONS OF CURCUMIN IN RATS.

Pic 1

BIOAVAILABILITY STUDIES – CURCUMIN & BIOPERINE

Pharmacokinetic parameters (mean + SEM) of oral curcumin 2 g alone and in combination with Bioperine® 20 mg in normal healthy volunteers (n=8).

Parameters
Curcumin alone
2 g
Curcumin+Bioperine®
2g+20mg
Cmax (mg/ml)
0.006 ± 0.005
0.18 ± 0.03
Tmax (h)
1
0.69 ± 0.07
t1/2(a) (h)
0.11 ± 0.02
t1/2(el) (h)
0.41 ± 0.17
AUC(0 – tn) (mg/h/ml)
0.004
0.08 ± 0.01
Vd (L/kg)
202.60 ± 78.94
Cl(L/h)
7.33 ± 1.25
F (Relative bioavailablility)
2000%

EFFECT OF BIOPERINE® ON SERUM CONCENTRATIONS OF CURCUMIN IN HUMAN VOLUNTEERS

Pic 3

[ Read More ]

Co Q10

 

Co Q10 – PHARMACOKINETIC EVALUATION unique difficulties:

  • Slow absorption from GI tract
  • Enterohepatic recycling
  • Endogenous Co Q10 production

Co Q10 – PHARMACOKINETIC MODEL

Graph 7

X0 : Gastrointestinal compartment
X1 : Plasma chylomicrons and the tissues where rapid distribution can take place
X2 : Liver
X3 : VLDL and tissues which are rapidly accessible to Co Q10

Plasma concentration of Co Q10 = X1 + X3

Pharmacokinetics of Coenzyme Q10. The increase in blood levels following a single oral intake of Coenzyme Q10 (90 mg) with and without Bioperine® (5mg)

Graph 8
Time of assay after a single dose administration of Coenzyme Q10

Absolute change in serum Coenzyme Q10 after 14 days supplementation of Coenzyme Q10 (90mg/day) with and without Bioperine® (5mg/day)

Graph 9

Graph 11

Effect of Bioperine® on serum CoQ10 levels during a 21 day supplementation trial.

Mean serum CoQ10 AUC values following supplementation of 120 mg of CoQ10 with and without 5 mg of Bioperine®

Graph 10

[ Read More ]

Vitamin C

 

Bioavailability of Vitamin C in presence of Drug, Propranolol.

Pharmacokinetic parameters of propranolol in the presence of Vitamin C and Bioperine®

1. Maximum plasma concentration C max (μg/ml)

Vitamin C

Standard Deviation: + 30%

Pharmacokinetic parameters of propranolol in the presence of Vitamin C and Bioperine®

1. Area under the concentration curve AUC μg/hr/ml {0 ⇒ TN}

Graph 12

Standard Deviation: + 30%

Pharmacokinetic parameters of Vitamin C in the presence of Propranolol and Bioperine®

1. Maximum plasma concentration C max (μg/ml)

Graph 11

Pharmacokinetic parameters of Vitamin C in the presence of Propranolol and Bioperine®

1. Area under the concentration curve AUC μg/hr/ml {0 ⇒ TN}

[ Read More ]

Vitamin B6

 
Vitamin B6Figure 3. Efficacy of Bioperine® on the bioavailability of Vitamin B6 absorption in human volunteers.

[ Read More ]

Selenium

 

Selenium Graph

Figure 2. Effect of Bioperine® on serum selenium levels during a 6 week supplementation trial.

[ Read More ]

Beta Carotene

 
Double-Blind, Crossover Design *
Volunteer #’s Phase I Phase II
# 1 thru # 6 β-Carotene+
placebo
β-Carotene+
Bioperine®
# 7 thru # 12 β-Carotene+
Bioperine®
β-Carotene+
placebo
* Phase I & Phase II supplementation periods occurred 12 weeks apart.
Serum Vitamin A Levels (mg/dl)
Treatment Baseline Day 14 Change
bβ-Carotene+
placebo
66.0 + 11.5 65.1 + 10.2 -0.9 + 2.4
β-Carotene+
Bioperine®
65.2 + 11.9 65.0 + 10.6 -0.2 + 2.1
Comparisons (baseline vs. Day 14, placebo vs. Bioperine® at Day 14, placebo vs. Bioperine® change at Day 14) indicated no statistically significant differences.
Serum β-Carotene levels (μg/dl)
Treatment Baseline Day 14 Change
bβ-Carotene+
placebo
16.3 + 2.6 47.2 + 6.4 30.9 + 5.4
β-Carotene+
Bioperine®
16.0 + 3.1 65.8 + 9.7 49.8 + 9.6
Comparisons (baseline vs. day 14, placebo vs. Bioperine®at Day 14, placebo vs. Bioperine® change at Day 14) indicated statistically significant differences (all p<0.0001)
Serum β-Carotene AUC Levels at Day 14
Treatment AUC
ug/dl/day
% Difference
β-Carotene+
placebo
272.0 + 47.6
β-Carotene+
Bioperine®
435.2 + 74.2 160
Comparison of AUC indicated a statistically significant difference (p<0.0001).

 

Graph 2

Figure 1. Effect of Bioperine® on the mean serum β-Carotene levels during a 14 day supplementation trial.

Graph 62

Summary

The relative bioavailability of β-Carotene is improved during a 14 day supplementation trail when it is ingested with Bioperine®

[ Read More ]

Slimirex® Weigh Loss Quick Help GHC on the Web
Follow us on the web: Google +1 Profile GHC on Youtube  GHC on Facebook  GHC on Twitter
Global Healing Center | 2040 North Loop West, Ste. 108 | Houston, Texas 77018
Telephone: 713-476-0016 | Toll Free: 1-800-476-0016 | Fax: 713-476-0017

DISCLAIMER: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Information and statements made are for education purposes and are not intended to replace the advice of your treating doctor. Global Healing Center does not dispense medical advice, prescribe, or diagnose illness. We design and recommend individual nutritional programs and supplements that allow the body to rebuild and heal itself. The views and nutritional advice expressed by Global Healing Center are not intended to be a substitute for conventional medical service. If you have a severe medical condition, see your physician of choice. This Web site contains links to Web sites operated by other parties. Such links are provided for your convenience and reference only. We are not responsible for the content or products of any linked site or any link contained in a linked site.

© Copyright 1998 - 2017 | All Rights Reserved slimirex.wpengine.com